Compounds > ziprasidone
Page last updated: 2024-08-24

ziprasidone and albendazole

ziprasidone has been researched along with albendazole in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L1
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR1

Reviews

1 review(s) available for ziprasidone and albendazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for ziprasidone and albendazole

ArticleYear
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
    Toxicology, 2005, Dec-15, Volume: 216, Issue:2-3

    Topics: Adenosine Triphosphate; Albendazole; Amitriptyline; Animals; Buthionine Sulfoximine; Carbamazepine; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Chromans; Coculture Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Activation; Flutamide; Glutathione; Humans; Isoniazid; Microsomes; Ochratoxins; Piperazines; Quinidine; Substrate Specificity; Tamoxifen; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Toxicity Tests; Triazolam; Troglitazone; Xenobiotics

2005
In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
    Drug metabolism letters, 2018, Volume: 12, Issue:2

    Topics: Acetates; Albendazole; Aldicarb; Biotransformation; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Methiocarb; Microsomes, Liver; Piperazines; Quinolines; Risk Assessment; Sulfides; Sulfones; Sulfoxides; Thiazoles; Triclabendazole

2018